AZN.L

Equity

ASTRAZENECA PLC ORD SHS $0.25

Health Care · Drug Manufacturers - General

$15,088.00

+15,088.00 (+0.00%)

Open

N/A

Day Range

$14,912.00 - $15,216.00

52W Range

$9,573.51 - $15,732.00

Volume

6M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
001540.KQ AHN-GOOK PHA $7,280.00 N/A 6.04% +0.00%
A Agilent Technologies, Inc. $120.24 N/A 0.83% +0.00%
ABUS Arbutus Biopharma Corporation $4.60 N/A - +0.00%
CRSP CRISPR Therapeutics AG $59.95 N/A - +0.00%
ABBV AbbVie Inc. $234.67 N/A 2.83% +0.00%
ABCL AbCellera Biologics Inc. $3.65 N/A - +0.00%
AKBA Akebia Therapeutics, Inc. $1.26 N/A - +0.00%
ACAD ACADIA Pharmaceuticals Inc. $23.06 N/A - +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About ASTRAZENECA PLC ORD SHS $0.25

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com →

🐂 Bull Score

Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.

F 16/100

Very Risky

Bull Score

~ Short dividend streak (1 years) 5/25
+ Good profit margin (17%) 11/15
Limited data — score may change as more metrics become available

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

60

Safe

Based on 4 fundamental factors

~ Recent dividend growth (1 yr)
~ Decent profit margins (17%)

Analysis Tools

Sign in for analysis tools

Share